FDA advisory panel backs AstraZeneca prostate cancer combo in decisive vote
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
